|
Home > Articles
Role of Positron Emission Tomography in Lung Cancer
Abstract
The ability to demonstrate tumour foci that are undetected by conventional imaging has resulted in the emergence of positron emission tomography (PET) as a valuable clinical tool in oncology. This article describes the technique and indications for fluorine-18 labelled fluorodeoxyglucose (18FDG)-PET in lung cancer, demonstrating the high accuracy and cost-effectiveness of 18FDG-PET in the characterisation of solitary pulmonary nodules and in the pre-operative staging of non-small cell lung cancer. Emerging roles in determination of prognosis, radiotherapy planning, therapy monitoring and diagnosis of recurrence are illustrated.
Author
K A Miles
Contact Details
Corresponding address:
K A Miles
Southernex Imaging & Queensland University of Technology,
The Wesley PET Centre
Department of Radiology
The Wesley Hospital
Auchenflower
Queensland
Australia
Reference
ICIS Cancer Imaging Volume 2
DOI: 10.1102/1470-7330.2002.0006
Date Posted
31 July 2002
Open Access is provided for this article.
Screen PDF
Size
193.53 KB
Minimum Estimated Download Times
ADSL 2Mb/s (Broadband): |
1 second |
ADSL 512Kb/s (Broadband): |
3 seconds |
64 Kb/s (ISDN): |
24 seconds |
33.3 Kb/s (Typical Modem): |
46 seconds |
Print PDF
Size
49.97 KB
Minimum Estimated Download Times
ADSL 2Mb/s (Broadband): |
1 second |
ADSL 512Kb/s (Broadband): |
1 second |
64 Kb/s (ISDN): |
6 seconds |
33.3 Kb/s (Typical Modem): |
12 seconds |
|
